Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
ConSynance Therapeutics General Information
CSTI-500 has completed three Phase 1 clinical trials, including two in healthy volunteers and one in PWS patients. The drug showed a similar efficacy profile in all three trials with no reported severe adverse events. PET imaging has revealed CSTI-500's brain target engagement in healthy volunteers. The FDA has granted Rare Pediatric Disease Designation (RPDD) to CSTI-500 for the treatment of PWS in children and adolescents.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Rensselaer, New York
United States
United States
Drug Pipeline
CSTI-500
Phase 2Key Partnerships
Harmony Biosciences (developing HBS-102), Member of the PWS Clinical Trial Consortium
ConSynance Therapeutics Funding
No funding data available
To view ConSynance Therapeutics's complete valuation and funding history, request access »